Figure 6

Cerebroprotective effect of antibody-mediated neutralization of dysregulated osteopontin at the neurovascular unit in acute ischemic stroke. Summary schematic depicting the anti-osteopontin antibody treatment regimens (top left panel) 4 h (single treatment duringt early acute phase) or 4 h and 15 h (combined treatment during early and late acute phase) after transient occlusion of middle cerebral artery (tMCAO) and their effects on dysregulated neurovascular unit (NVU) and blood–brain barrier (BBB) function in the ischemic cerebrovascular bed (bottom panel) and on hemorrhagic transformation, cerebral edema formation and stroke volume (top right panel) 24 h post-tMCAO in mice.